Betacellulin (BTC) is a potent epidermal growth factor (EGF) family ligand that binds and activates both EGFR (ErbB1) and ErbB4 (HER4) homodimers and heterodimers. While historically studied for its role in pancreatic beta-cell regeneration, BTC is increasingly recognized as a key driver of oncogenesis, epithelial-to-mesenchymal transition (EMT), and resistance to standard anti-EGFR therapies. Developing therapeutics that target the BTC-EGFR/ErbB4 axis requires highly specific, conformationally correct reagents to differentiate candidate molecules from broad EGF-family inhibitors and avoid off-target toxicities.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BTC drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BTC ECD-Fc / Mature Peptide High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View BTC Products |
| Gene Delivery | BTC Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based signaling and internalization assays. |
View BTC Products |
| Benchmark Ab | Anti-BTC Recombinant Antibody Recombinant positive control derived from clinical-stage/validated sequences. |
View BTC Products |
| Validator | BTC siRNA Set For target knockdown verification and specificity profiling in tumor cell lines. |
View BTC Products |
| Related Target A | EGFR Primary receptor for BTC. Essential for dual-targeting and receptor competition profiling. |
View EGFR Products |
| Related Target B | ERBB4 Alternative receptor for BTC. Crucial for evaluating off-target or secondary signaling pathways. |
View ERBB4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus BTC ortholog proteins available with >95% purity and verified theoretical MW. |
| EGF-family subfamily counter screening | Homolog panel proteins (EGF, HB-EGF, TGF-alpha) strictly verified by mass spectrometry to guarantee no cross-contamination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives in Knockdown | Sequence-verified siRNA included for precise target specificity checks. |
Live BTC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BTC-targeted therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies (mAbs) to antibody-drug conjugates (ADCs) and bispecific antibodies. Because pro-BTC is expressed as a membrane-bound precursor before being cleaved into its soluble form, it presents a unique tumor-associated antigen profile. As first-generation EGFR therapies encounter resistance via ligand upregulation, the next wave of R&D is targeting BTC to block compensatory ErbB pathway activation and bypass resistance mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | Oncology Biotechs, Pharma | Solid Tumors (Breast, Ovarian, Lung) | Internalization Assay (Need high-purity transmembrane pro-BTC or ECD-Fc for binding) |
| Bispecific / Multi-specific | Immunotherapy Innovators | EGFR-TKI Resistant Non-Small Cell Lung Cancer (NSCLC) | Heterodimer Validation (Need cross-reactive EGFR and ERBB4 proteins to verify simultaneous binding) |
| Ligand Traps / Small Molecules | Translational Medicine Groups | Pancreatic Cancer, Advanced Solid Tumors | Selectivity Assay (Need Mutant vs WT Receptors and a complete EGF family panel) |